L-Alanosine
Based on 1 publication(s) in Google Scholar
L-Alanosine (NSC-153353), an antibiotic from Streptomyces alanosinicus, has antineoplastic activity. L-Alanosine (NSC-153353) inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate. L-Alanosine is the inhibitor for methylthioadenosine phosphorylase (MTAP).
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 5854-93-3
- Formula: C3H7N3O4
- Molecular Weight:149.11
-
Storage:Powder -20°C, 3 years
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) L-Alanosine
MoreAll Antibiotic Isoforms
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
L-Alanosine (0.1-100 μM, 10 days) blocks the de novo purine synthesis pathway by inhibiting the activity of adenylosuccinate synthetase (ADSS), thereby inhibiting the proliferation of MTAP-deficient tumor cells CEM/ADR5000, HL-60/AR and MDA-MB-231-BCRP because these cells cannot obtain adenine through the salvage pathway[1].
L-Alanosine (0.125-0.25 μM, 14 days) inhibits the mitochondrial function (especially mitochondrial spare respiratory capacity), reduces the stemness of GBM cells, increases a synergistic inhibitory effect with Temozolomide (HY-17364)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CEM/ADR5000, HL-60/AR, MDA-MB-231-BCRP
-
Concentration:0.1-100 μM
-
Incubation Time:10 days
-
Result:Inhibited cell growth.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:GBM 12-0160 xenograft mouse models[4]
-
Dosage:150 mg/kg
-
Administration:ip, three times a week for 7 weeks
-
Result:Inhibited tumor growth, prolonged the survival rate.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 5854-93-3
-
Appearance Solid
-
Molecular Weight 149.11
-
Formula C3H7N3O4
-
Color White to yellow
-
SMILES
N[C@@H](CN(O)N=O)C(O)=O
-
Synonyms
NSC-153353; SDX-102
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. [Abstract]2021 Oct 1;81(19):4964-4980. PMID: 34385182
Solvent & Solubility
H2O : 50 mg/mL (335.32 mM; Need ultrasonic)
H2O : 15 mg/mL (100.60 mM; ultrasonic and adjust pH to 8 with NaOH)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Efferth T, et al. Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem Pharmacol. 2003 Aug 15;66(4):613-21. [Content Brief]
[2]. Chitnis MP, et al. Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias. Tumori. 1984 Aug 31;70(4):317-20. [Content Brief]
[3]. Tyagi AK, et al. Identification of the antimetabolite of L-alanosine, L-alanosyl-5-amino-4-imidazolecarboxylic acid ribonucleotide, in tumors and assessment of its inhibition of adenylosuccinate synthetase. Cancer Res. 1980 Dec;40(12):4390-7. [Content Brief]
[4]. Singh SX, et al., Purine Synthesis Inhibitor L-Alanosine Impairs Mitochondrial Function and Stemness of Brain Tumor Initiating Cells. Biomedicines. 2022 Mar 23;10(4):751. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / H2O | 1 mM | 6.7065 mL | 33.5323 mL | 67.0646 mL | 167.6615 mL |
| 5 mM | 1.3413 mL | 6.7065 mL | 13.4129 mL | 33.5323 mL | |
| 10 mM | 0.6706 mL | 3.3532 mL | 6.7065 mL | 16.7661 mL | |
| 15 mM | 0.4471 mL | 2.2355 mL | 4.4710 mL | 11.1774 mL | |
| 20 mM | 0.3353 mL | 1.6766 mL | 3.3532 mL | 8.3831 mL | |
| 25 mM | 0.2683 mL | 1.3413 mL | 2.6826 mL | 6.7065 mL | |
| 30 mM | 0.2235 mL | 1.1177 mL | 2.2355 mL | 5.5887 mL | |
| 40 mM | 0.1677 mL | 0.8383 mL | 1.6766 mL | 4.1915 mL | |
| 50 mM | 0.1341 mL | 0.6706 mL | 1.3413 mL | 3.3532 mL | |
| 60 mM | 0.1118 mL | 0.5589 mL | 1.1177 mL | 2.7944 mL | |
| 80 mM | 0.0838 mL | 0.4192 mL | 0.8383 mL | 2.0958 mL | |
| 100 mM | 0.0671 mL | 0.3353 mL | 0.6706 mL | 1.6766 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
L-Alanosine Related Classifications
HY-16933 Related Classifications
Powered by Bioz